MeSH D001416 - back pain
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Naproxen | Naproxen | 1995-02-28 | |||
| Glenmark Pharmaceuticals | Naproxen | Naproxen | 2007-03-28 | |||
| Mylan | Naproxen | Naproxen | 1993-12-21 | |||
| Esomeprazole, Naproxen | Naproxen Esomeprazole Magnesium | 2021-07-20 | ||||
| Perrigo | Naproxen | Naproxen | 1997-01-13 | |||
| Naproxen, Diphenhydramine | Naproxen Diphenhydramine | 2019-05-10 | ||||
| Pseudoephedrine, Naproxen | Naproxen Pseudoephedrine | 2004-03-17 | ||||
| P&L Developments (PLD) | Naproxen, Diphenhydramine | Naproxen Diphenhydramine | 2019-01-25 | |||
| Cipla | Naproxen | Naproxen | 2011-08-24 | |||
| Sandoz | Naproxen | Naproxen | 1993-12-21 | |||
| Bayer | Naproxen, Pseudoephedrine, Diphenhydramine | Aleve | 1994-01-11 | |||
| Takeda | Naproxen, Lansoprazole | Prevacid Naprapac | 2003-11-14 | |||
| Aurobindo Pharma | Naproxen | Naproxen | 2001-04-19 | |||
| Pseudoephedrine, Naproxen | Naproxen Pseudoephedrine | 2022-06-01 | ||||
| Naproxen, Sumatriptan | Sumatriptan Naproxen | 2018-02-15 |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
78%7/9
Phase 2
35%8/23
Phase 3
59%24/41
Approved: 3Overall Success rate: 16%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use